Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell Carcinoma

Oncologist - United States
doi 10.1634/theoncologist.12-1-107
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2016English

Drug Repurposing for Gastrointestinal Stromal Tumor

Molecular Cancer Therapeutics
Cancer ResearchOncology
2013English

Transparency and Dermatologic Device Approval by the US Food and Drug Administration

JAMA Dermatology
DermatologyMedicine
2018English

Safety and Efficacy of Sunitinib for Advanced Non-Clear Cell Renal Cell Carcinoma

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2015English

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis

Clinical Cancer Research
Cancer ResearchOncology
2012English

Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–resistant Patients: Recommendations and Evidence

Current Oncology
Oncology
2010English

Crosstalk Between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance

Cancer Research
Cancer ResearchOncology
2014English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Have Thoracic Endografting Outcomes Improved Since US Food and Drug Administration Approval?

Annals of Thoracic Surgery
Respiratory MedicinePulmonaryCardiovascular MedicineSurgeryCardiology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy